Literature DB >> 15719387

Herpes zoster infection after liver transplantation: a case-control study.

Josh Levitsky1, Andre Kalil, Jane L Meza, Glenn E Hurst, Alison Freifeld.   

Abstract

Prior case series have suggested that herpes zoster (HZ) after orthotopic liver transplantation (OLT) may lead to serious complications due to visceral involvement. We sought to determine the incidence, risk factors, and long term outcomes of HZ after OLT. Clinical data from September 1993 to April 2004 were collected on all cases of HZ after OLT, and at the same post-OLT time points in age, gender, and transplant-year-matched HZ-negative controls. Risk factors for HZ infection and long-term outcomes were compared between cases and controls. A total of 29 patients developed HZ at a median of 4.9 years (range .5-12.9) after OLT. All HZ infections except 1 were localized to a single dermatome. Only 8 (28%) were hospitalized and 16 (55%) were treated with oral antivirals alone. No patients developed visceral involvement or died of HZ infection. No risk factors for HZ infection were identified on multivariate analysis. Of the long-term outcomes, the estimated 10-year survival was lower (P = .05) for cases than controls. The lower survival in HZ cases was not directly attributable to HZ infection. In conclusion, this study is the largest series on HZ after OLT. HZ is neither a common nor a serious infection after OLT and can be managed with antiviral therapy with a low likelihood of visceral dissemination.

Entities:  

Mesh:

Year:  2005        PMID: 15719387     DOI: 10.1002/lt.20356

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  9 in total

1.  Recommendations for the assessment and reporting of multivariable logistic regression in transplantation literature.

Authors:  A C Kalil; J Mattei; D F Florescu; J Sun; R S Kalil
Journal:  Am J Transplant       Date:  2010-07       Impact factor: 8.086

2.  Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation.

Authors:  Robert J Fontana; Eric A Hughes; Henry Appelman; Robert Hindes; Dessislava Dimitrova; Marc Bifano
Journal:  Liver Transpl       Date:  2012-09       Impact factor: 5.799

3.  Herpes zoster incidence in a multicenter cohort of solid organ transplant recipients.

Authors:  S A Pergam; C W Forsberg; M J Boeckh; C Maynard; A P Limaye; A Wald; N L Smith; B A Young
Journal:  Transpl Infect Dis       Date:  2011-02       Impact factor: 2.228

4.  Incidence and risk factors for herpes zoster after adult liver transplantation.

Authors:  Wontae Kim; Sangjin Kim; Jongwook Oh; Young Jae Jeong; Jinsoo Rhu; Kyung Sik Kim; Jisoo Lee; Gyu-Sung Choi; Jong Man Kim; Jae-Won Joh
Journal:  Ann Surg Treat Res       Date:  2018-01-30       Impact factor: 1.859

5.  Infectious Complications After Liver Transplantation.

Authors:  Maria Del Pilar Hernandez; Paul Martin; Jacques Simkins
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-11

6.  Herpes Zoster Risk in Immunocompromised Adults in the United States: A Systematic Review.

Authors:  Susannah L McKay; Angela Guo; Steven A Pergam; Kathleen Dooling
Journal:  Clin Infect Dis       Date:  2020-10-23       Impact factor: 9.079

7.  Incidence and risk factors of herpes zoster among adult renal transplant recipients receiving universal antiviral prophylaxis.

Authors:  Ioanna D Pavlopoulou; Stavroula Poulopoulou; Christina Melexopoulou; Ioanna Papazaharia; George Zavos; Ioannis N Boletis
Journal:  BMC Infect Dis       Date:  2015-07-24       Impact factor: 3.090

Review 8.  Herpesvirus Respiratory Infections in Immunocompromised Patients: Epidemiology, Management, and Outcomes.

Authors:  Gail E Reid; Joseph P Lynch; Samuel Weigt; David Sayah; John A Belperio; Shellee A Grim; Nina M Clark
Journal:  Semin Respir Crit Care Med       Date:  2016-08-03       Impact factor: 3.119

9.  No increased risk of herpes zoster found in cirrhotic patients: a nationwide population-based study in Taiwan.

Authors:  Ping-Hsun Wu; Yi-Ting Lin; Chun-Nan Kuo; Wei-Chiao Chang; Wei-Pin Chang
Journal:  PLoS One       Date:  2014-04-03       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.